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Introducing Magnesium Sulphate for the
Management of Pregnancy Induced
Hypertension

G

lobal studies1 have demonstrated that using
magnesium sulphate (MgSO4) to manage
hypertensive disease in pregnancy, reduces
morbidity and mortality due to severe pre
eclampsia and eclampsia, one of the five direct
causes of maternal death. Major signs of pre
eclampsia/eclampsia include high blood
pressure, protein in the urine, swelling of the
feet, hands and face leading to convulsions
(fitting) and coma.
Women are not always given anti hypertensives
to control the high blood pressure and
Diazepam is often the only drug used to control
eclamptic fits. However this is a sedative and
not an anticonvulsant. MgSO4 on the other
hand does not sedate pregnant women and
they are alert throughout.

Many countries have been slow to introduce
MgSO4 to the detriment of women’s health.
Hypertensive disease in pregnancy (Eclampsia)
is the second most frequent direct cause of
maternal death in Western Province, Kenya at
16% after haemorrhage (22%).2 In one district
hospital all women admitted during 2003 with
eclampsia died. There are also critical gaps3 in
health care provider knowledge, skills and
practice in management of eclampsia.
In Essential Obstetric Care and Life Saving
Skills training the use of MgSO4 is advocated
and many health care providers know about it
in theory but the drug is difficult to obtain and
is not part of the essential drugs list available
to public health facilities.
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Emergency resuscitation trays in maternity
units do not always have essential components
required: patella hammer (for testing reflexes
in patient on MgSO4), calcium gluconate
(antidote to MgSO4) and uristix to detect
protein in the urine.
Although the use of MgSO4 was introduced
successfully to the Maternity Unit at Kenyatta
National Hospital, Nairobi in 2001, there has
been no systematic introduction of the drug
across the country. Generally the only facilities
utilising MgSO4 are those supported by
development partners and some mission
hospitals.
In response to health care managers and
providers request in Western Province to be
trained in the use of MgSO4, a two-day
practical training programme was developed.

Training
The main objective for the On Job Training was
to ensure that participants had specific skills
of preventing and managing severe pre
eclampsia and eclampsia. In addition the
necessary equipment, supplies and MgSO4
were made available to the facilities where
health care providers were trained. Laminated
flow-charts illustrating the administration of the
drug were distributed for display in the
maternity units.
During support supervision two months after
the two day training the following were found:
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33 out of 44 (75%) of maternity staff
but specifically at the facility level and the drug
interviewed were comfortable using
must be placed on the Essential Drug List. The
MgSO4
following issues will need to be included in the

9 out of 15 (60%) of eclamptic mothers
RH policy:
had received MgSO4

All 6 mothers admitted to PGH with

Magnesium Sulphate for the
severe pre-eclampsia were treated
management of PIH to be licensed
successfully with MgSO4

Magnesium sulphate to be manufactured

Twenty-nine mothers admitted with
in Kenya – within hospitals or
severe pre-eclampsia in the other
institutions regulated to do so.
hospitals did not receive MgSO4 as

Advocacy at all levels to inform women,
providers were only using it for patients
families and communities on
who were convulsing. More MgSO4 was
effectiveness of drug
made available and further OJT rectified

Ensure effective Focussed Antenatal Care
this.
to detect signs of pre-eclampsia early

There were no adverse effects reported

Ensure equipment and supplies are
on mothers who received MgSO4
available for prevention of HIP specifically
• Staff who had attended the training
BP machines and uristix (for detection of
reported that they now preferred to use
proteinuria) at all levels of health facility.
MgSO4 for
managing
patients with pre“It is a wonder drug, the patient
Conclusion
eclampsia and
stopped convulsing and was
International and national
eclampsia.
fully conscious all through, had
evidence has proved MgSO4 as
a normal vaginal delivery and
the drug of choice for the
after 4 days was discharged
management of pregnancy
Challenges
with her baby.”
induced
hypertension/
The main challenges
eclampsia. Practical training can
to implementing a
take place on the ward within
programme such as this include:
one day with close supervsion. MgSO4 is both

Reluctance of some senior health care
cheap and effective and has already saved
providers to introduce the drug in their
many lives since it was introduced in Western
facilities due to lack of up to date
Province.
information

Ensuring essential drugs, supplies and
equipment always available

Continuous education to ensure newly
deployed staff are conversant in use of
Mg SO4

Late referrals from the community;


Policy Implications
For Magnesium Sulphate to become the routine
drug of choice for the management of
pregnancy-induced hypertension, this
information must be disseminated and
clarified at all levels
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